Success Metrics

Active Trials
5(83%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
2
33%
Ph phase_3
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

recruiting583%
not_yet_recruiting117%

Recent Activity

5 active trials
Showing 5 of 6
recruitingphase_3

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511
recruitingphase_1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335
recruitingphase_1

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

NCT06768489
not_yet_recruitingphase_3

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186
recruitingphase_2

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07258511Phase 3

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT05652335Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Recruiting
NCT06768489Phase 1

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Recruiting
NCT07518186Phase 3

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Not Yet Recruiting
NCT07266441Phase 2

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT05695508Phase 2

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6